Metabolic labeling of IGFBP-5 by T47D breast carcinoma cells

Slides:



Advertisements
Similar presentations
2D PAGE/Western blotting analysis for the identification of possible post-translation modification of Hsp27 from the spinal cord tissue of the SCI rat.
Advertisements

PLGEM parameters are reasonably stable to decreasing number of replicates. PLGEM parameters are reasonably stable to decreasing number of replicates. A.
Sequence alignment of C-terminal phosphorylated plant aquaporins
Distribution of phosphorylation sites identified in the cytosolic phosphoproteome.A, numbers of approved phosphopeptides, previously phosphorylated peptides,
Microvesicles released by PC-3 cells.
Analysis of CDCP1 as a potential prostate cancer biomarker.
Fast protein LC IMAC purification of cytosolic phosphoproteins
A quantitative proteomics strategy to identify SUMO-conjugated proteins. A quantitative proteomics strategy to identify SUMO-conjugated proteins. HeLa.
Differential conjugation of endogenous SUMO-1 and endogenous SUMO-2/3 to target proteins.A and B, SUMO-1 and SUMO-2 proteins were produced in E coli and.
Frequency distribution of the GRAVY of the theoretical proteins (open bars) and of 110 genes encoding proteins identified on a 2-D electrophoresis gel,
Separation of embryonic brain proteins and peptides by sequential preparative SDS-PAGE and SCX chromatography.A, 6 mg of embryonic day 16.5 murine brain.
Relative quantitation of phosphopeptides from conditioned media from subtype specific breast cancer cell lines. Relative quantitation of phosphopeptides.
Time course of phosphorylation changes at Ser-293, Ser-300, and Ser-232 in PDHE1α following kinase inhibition with DCA. A, relative quantitation over three.
Two-dimensional electrophoresis results and validation with Western blotting. Two-dimensional electrophoresis results and validation with Western blotting.
Expression of apocrine markers at various stages of apocrine carcinoma progression. Expression of apocrine markers at various stages of apocrine carcinoma.
Experimental setup.A, topology models of the overexpressed membrane protein GFP fusions. Experimental setup.A, topology models of the overexpressed membrane.
Bottom-up proteomic characterization of MALDI IMS samples.
Success rates in validation of antibodies from external providers
Results from the Morris water task.
A, myelinated nerve fibers in the control and biopsied mouse striatum were stained with anti-MBP antibody. A, myelinated nerve fibers in the control and.
NanoLC-MS/MS/based analysis of proteome differences between colonospheres and isogenic differentiated tumor cells. NanoLC-MS/MS/based analysis of proteome.
BIRC6 is expressed in the tumorigenic Aldefluorhigh fraction of colonosphere cells. BIRC6 is expressed in the tumorigenic Aldefluorhigh fraction of colonosphere.
Colonopshere-enriched proteins display functional interactions.
A, schematic presentation of fetuin-A domains.
Proteins previously reported in published MALDI IMS studies and their frequency of observation in the present study. Proteins previously reported in published.
N-terminal extension of a gene using peptides mapping upstream to an annotated start site. N-terminal extension of a gene using peptides mapping upstream.
BIRC6 confers resistance against cisplatin and oxaliplatin.
Changes in bacterial adhesion with hmLF addition and the purified glycan from hmLF. Changes in bacterial adhesion with hmLF addition and the purified glycan.
Protein microarrays for validation of antibodies.
A, Western blot analysis of fetuin-A in AGA (lanes 1–5 and 10–13) and IUGR (lanes 6–9, 14, and 15) UC plasma samples. A, Western blot analysis of fetuin-A.
Manual assessment of the quality of peptide spectra with scores ranging from 5 to 10 of OFFGEL electrophoresis fractions 3 and 4 that were rejected by.
Testing the effectiveness of the three-step peptide fractionation method.A, μLC mass chromatograms of SCX fractions for an acidic FFE fraction. Testing.
Altered pathways in prostate cancer.
IEF 2D PAGE of whole protein extracts from breast apocrine macrocysts
The PPAR-α agonist GW7647 reduces experimentally induced myopia.
Analysis of E. coli peptides by OFFGEL electrophoresis and HPLC-Chip/MS.a, total number of peptides identified (id.) in each fraction; the dark shaded.
Plot of the deviation of the predicted pI value of every peptide spectrum from the average pI calculated for each fraction for validated (a) and non-validated.
Distribution of the phosphoproteins based on GO analysis, including biological process (Left) and cellular component (Right). Distribution of the phosphoproteins.
Examples of protein that display profiles corresponding to GO/GROW and STOP signals.A, example of STOP profile: normalized spot volume profile of apoA-I.
Extraction of proteins from MALDI IMS slides.
Differential expression of apoA-I and Vimentin on 2D gels
Significant alterations in cysteine and methionine metabolism.
K-Means clustering of protein and mRNA expression patterns after PPAR agonists treatments. k-Means clustering of protein and mRNA expression patterns after.
Number of genes/antibodies included in the database.
Bar plot representation of the transcriptomic changes in Δsaci_ptp and Δsaci_pp2a. Bar plot representation of the transcriptomic changes in Δsaci_ptp and.
Western blot analysis of fetuin-A in AGA and IUGR UC plasma after digestion with glycosidases showing the elimination of the IUGR-related isoforms following.
Preferential conjugation of proteins to SUMO-1 or SUMO-2
Illustration of chromatography metric C-2A applied to LC-MS/MS data from three Thermo LTQ systems in analyses of yeast proteome samples in CPTAC Study.
Quantitation of phosphopeptides binding to and recovered from different types of IMAC material.32P-labeled phosphopeptides were produced by in vitro autophosphorylation.
Classification of the 1458 identified proteins into molecular functions. Classification of the 1458 identified proteins into molecular functions. The pie.
Proteomic analysis of externalized proteins
Illustration of σ down-regulation in bladder carcinomas.
Immunoblot analysis of apoptotic HCT-8 cell extracts separated by SDS-PAGE. Immunoblot analysis of apoptotic HCT-8 cell extracts separated by SDS-PAGE.
Proteomic analysis of invasive TCCs
Expression of σ in SCCs Expression of σ in SCCs. Shown is a magnified section of a representative 2D PAGE gel run with a lysate from an SCC.
Antibody specificity ascertained by 2D-PAGE Western immunoblotting (IEF) of total cellular protein extracts from the RT4 human bladder cancer cell line.
Influence of MS measurement conditions on the deviation factors between the estimated and measured concentrations of 46 proteins in neuro2a cells.A, QSTAR.
Western blotting analysis of purified cytoplasmic membranes.
Tryptic phosphopeptides of AdIGFBP-5, [γ-32P]ATP-labeled in vitro by phosphorylation with CK2, were separated by HPLC and detected and sequenced by mass.
SDS-PAGE of IGFBP-5 from 32P-labeled T47D cells and separation of tryptic phosphopeptides separated by HPLC.a, an autoradiograph (lane 1) is shown next.
Functional studies of dephosphorylated and deglycosylated adenoviral vector-derived IGFBP-5.a, untreated IGFBP-5 (lane 1), Antarctic phosphatase-treated.
Tryptic phosphopeptides of 32P-labeled IGFBP-5 from T47D cells separated by HPLC and sequenced by tandem MS.a, tandem MS spectrum of the triply charged.
Tryptic glycopeptides of IGFBP-5 from T47D cells separated by HPLC detected by ESI-MS and sequenced by tandem MS.a, ESI-MS spectrum of combined fractions.
The role of CK2 in IGFBP-5 phosphorylation
Eight serum analytes with greatest differences in levels between clinically infected and non-infected neonates. Eight serum analytes with greatest differences.
Full-length AdIGFBP-5 and T47D cell-derived IGFBP-5 analyzed by mass spectrometry.a, intact AdIGFBP-5 was analyzed by ESI-MS. Full-length AdIGFBP-5 and.
SiRNA knockdown of dynein IC2-C recovered the inhibition of neurite outgrowth in NF1-KD PC12 cells. siRNA knockdown of dynein IC2-C recovered the inhibition.
The average median S.D. and PEV reduction after applying different normalization methods compared with raw data. The average median S.D. and PEV reduction.
Comparison of fluorescence spectra of cells expressing the FL-IFN-γR2/EBFP and FL-IFN-γR2/GFP chains in the presence and absence of the IFN-γR1 chain and.
Model of the change in receptor structure on engagement of the ligand IFN-γ. Model of the change in receptor structure on engagement of the ligand IFN-γ.
Presentation transcript:

Metabolic labeling of IGFBP-5 by T47D breast carcinoma cells Metabolic labeling of IGFBP-5 by T47D breast carcinoma cells.a, cells were cultured in the presence of [32P]orthophosphoric acid, and IGFBP-5 in conditioned media was detected by Western immunoblotting (WIB) and autoradiography after SDS-PAGE. b, conditioned media from non-radioactive replicate wells were collected at time points up to 12 h, and levels of secreted IGFBP-2 (open bars) and -5 (closed bars) were quantitated by RIA. c, T47D breast carcinoma cell-derived IGFBPs were purified by IGF-I affinity chromatography and then fractionated by reverse-phase HPLC. UV absorbance is indicated on the left axis, and percent Phase B (60% acetonitrile in 0.1% TFA) is indicated on the right axis. Metabolic labeling of IGFBP-5 by T47D breast carcinoma cells.a, cells were cultured in the presence of [32P]orthophosphoric acid, and IGFBP-5 in conditioned media was detected by Western immunoblotting (WIB) and autoradiography after SDS-PAGE. b, conditioned media from non-radioactive replicate wells were collected at time points up to 12 h, and levels of secreted IGFBP-2 (open bars) and -5 (closed bars) were quantitated by RIA. c, T47D breast carcinoma cell-derived IGFBPs were purified by IGF-I affinity chromatography and then fractionated by reverse-phase HPLC. UV absorbance is indicated on the left axis, and percent Phase B (60% acetonitrile in 0.1% TFA) is indicated on the right axis. An autoradiograph of a ligand blot of the HPLC fractions 26–37 inclusive using 125I-IGF-I is shown in the inset and overlaid at the appropriate retention times. Mark E. Graham et al. Mol Cell Proteomics 2007;6:1392-1405 © 2007 The American Society for Biochemistry and Molecular Biology